This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectrum Pharmaceuticals Initiates Phase 3 Study Of ZEVALIN® In Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL); Most Common Form Of Aggressive Non-Hodgkin’s Lymphoma

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced initiation of patient enrollment in the Company’s randomized Phase 3 ZEST ( Zevalin Evaluation as Sequential Therapy) trial of ZEVALIN ® (ibritumomab tiuxetan) Injection for intravenous use for first-line consolidation in patients with diffuse large B-cell lymphoma (DLBCL) who achieved remission following R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). The study will assess overall survival (OS) and progression-free survival (PFS) in patients 60 years and older. Patients will consist of newly diagnosed Stage II – IV DLBCL patients with a complete response after the standard six courses of R-CHOP. They will be randomized between observation and ZEVALIN treatment.

“Initiation of the ZEST trial, together with our commitment to the ongoing SPINOZA trial in patients with relapsed DLBCL who receive autologous stem cell transplantation, represent a comprehensive clinical program to determine the full potential of ZEVALIN in DLBCL, the most common form of non-Hodgkin’s lymphoma in which there is substantial unmet need, especially in older patients,” stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc.

Dr. Shrotriya continued, “Spectrum has a number of near-term and long-term clinical milestones for ZEVALIN, including presentations at major medical meetings, both internationally and in the US, such as at ASH and ASCO. In addition, a patient initiative launched earlier this year and the acquisition of marketing rights in the EU should have a strong impact on increasing awareness of the value of this important product for the global lymphoma community.”

Paul Hamlin, M.D., of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center and a lead investigator in the study, commented, “There is a substantial need for better treatments for DLBCL, particularly in the ever-increasing group of older patients who have fewer treatment options than younger patients. A consolidative therapy that is administered in just one week and improves survival would have a huge impact on lymphoma patients’ lives. The very encouraging evidence from earlier Phase 2 studies of ZEVALIN in aggressive lymphomas, both in terms of safety and efficacy results, form the basis for the randomized study, and ZEVALIN has the potential to expand our arsenal against this terrible disease.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs